| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
57,760,000 |
| Market
Cap: |
773.41(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$7.15 - $14.91 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Evolus is a beauty company focused on delivering products in the self-pay aesthetic market. Co.'s commercial product is Jeuveau® (prabotulinumtoxinA-xvfs), a proprietary purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Co.'s primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
174,967 |
224,934 |
| Total Buy Value |
$0 |
$0 |
$1,296,505 |
$1,776,503 |
| Total People Bought |
0 |
0 |
1 |
4 |
| Total Buy Transactions |
0 |
0 |
1 |
7 |
| Total Shares Sold |
147,425 |
242,004 |
1,955,045 |
6,452,816 |
| Total Sell Value |
$2,042,809 |
$3,021,938 |
$15,929,922 |
$55,083,596 |
| Total People Sold |
3 |
4 |
5 |
8 |
| Total Sell Transactions |
7 |
10 |
15 |
33 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Moatazedi David |
See Remarks |
• • – |
2023-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
187,927 |
679,888 |
|
- |
|
| Avelar Rui |
See Remarks |
• – – |
2023-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
97,642 |
350,831 |
|
- |
|
| Beaver Sandra |
Chief Financial Officer |
• – – |
2023-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
62,642 |
99,085 |
|
- |
|
| Medytox Inc. |
10% Owner |
– – • |
2023-01-20 |
4 |
S |
$11.04 |
$408,955 |
I/I |
(37,043) |
7,259,500 |
|
18% |
|
| Medytox Inc. |
10% Owner |
– – • |
2022-10-06 |
4 |
S |
$8.99 |
$344,418 |
D/D |
(38,304) |
7,259,500 |
|
-4% |
|
| Medytox Inc. |
10% Owner |
– – • |
2022-10-05 |
4 |
S |
$8.95 |
$61,290 |
D/D |
(6,848) |
7,297,804 |
|
-6% |
|
| Medytox Inc. |
10% Owner |
– – • |
2022-09-15 |
4 |
S |
$10.34 |
$248,105 |
D/D |
(24,000) |
7,304,652 |
|
-1% |
|
| Medytox Inc. |
10% Owner |
– – • |
2022-09-14 |
4 |
S |
$10.27 |
$749,674 |
D/D |
(73,000) |
7,328,652 |
|
0% |
|
| Hayman Robert |
Director |
– • – |
2022-09-12 |
4 |
B |
$10.78 |
$11,756 |
I/I |
1,091 |
10,000 |
2.1 |
1% |
|
| Hayman Robert |
Director |
– • – |
2022-09-09 |
4 |
B |
$10.35 |
$92,182 |
I/I |
8,909 |
8,909 |
2.1 |
6% |
|
| Medytox Inc. |
10% Owner |
– – • |
2022-09-09 |
4 |
S |
$10.53 |
$217,911 |
D/D |
(20,700) |
7,401,652 |
|
-6% |
|
| Medytox Inc. |
10% Owner |
– – • |
2022-09-08 |
4 |
S |
$10.39 |
$158,979 |
D/D |
(15,300) |
7,422,352 |
|
-6% |
|
| Hayman Robert |
Director |
– • – |
2022-09-07 |
4/A |
B |
$10.05 |
$50,250 |
D/D |
5,000 |
39,881 |
2.39 |
- |
|
| Hayman Robert |
Director |
– • – |
2022-09-07 |
4 |
B |
$10.05 |
$49,918 |
D/D |
4,967 |
39,848 |
2.39 |
3% |
|
| Blank Simone |
Director |
– • – |
2022-09-06 |
4 |
B |
$9.24 |
$184,844 |
D/D |
20,000 |
54,881 |
2.39 |
11% |
|
| Farrell Peter C |
Director |
– • – |
2022-09-06 |
4 |
B |
$9.10 |
$91,048 |
I/I |
10,000 |
10,000 |
2.1 |
11% |
|
| Beaver Sandra |
Chief Financial Officer |
• – – |
2022-09-05 |
4 |
A |
$0.00 |
$0 |
D/D |
36,443 |
36,443 |
|
- |
|
| Medytox Inc. |
10% Owner |
– – • |
2022-08-01 |
4 |
S |
$13.28 |
$345,361 |
D/D |
(26,000) |
7,437,652 |
|
43% |
|
| Silvernail Lauren P |
See Remarks |
• – – |
2022-05-18 |
4 |
S |
$12.42 |
$646,026 |
D/D |
(52,015) |
141,571 |
|
35% |
|
| Silvernail Lauren P |
See Remarks |
• – – |
2022-05-17 |
4 |
S |
$13.92 |
$225,354 |
D/D |
(16,189) |
193,586 |
|
43% |
|
| Moatazedi David |
See Remarks |
• • – |
2022-05-16 |
4 |
S |
$13.64 |
$754,307 |
D/D |
(55,321) |
491,961 |
|
42% |
|
| Gill David N |
Director |
– • – |
2022-05-16 |
4 |
S |
$13.62 |
$68,080 |
D/D |
(5,000) |
29,568 |
|
42% |
|
| Gill David N |
Director |
– • – |
2022-05-13 |
4 |
S |
$13.10 |
$69,584 |
D/D |
(5,313) |
34,568 |
|
37% |
|
| Moatazedi David |
See Remarks |
• • – |
2022-03-28 |
4 |
AS |
$11.62 |
$70,928 |
D/D |
(6,104) |
547,282 |
|
-19% |
|
| Moatazedi David |
See Remarks |
• • – |
2022-03-08 |
4 |
AS |
$9.73 |
$369,293 |
D/D |
(37,972) |
553,386 |
|
30% |
|
183 Records found
|
|
Page 3 of 8 |
|
|
0.09 (0.68%) 
